Varex Imaging Corporation (VREX) filed a current report to announce that it has released a press release with its preliminary operating results for the twelve months ended October 3, 2025. The press release, titled “Varex Announces Financial Results for Fourth Quarter and Fiscal Year 2025,” is furnished as Exhibit 99.1 to the report and provides details on the company’s fourth quarter and full fiscal year 2025 performance. The company specifies that this information is being furnished under the securities laws rather than formally filed, which affects how it may be used in other regulatory documents.
Varex Imaging (VREX) insider filing: The company’s Chief Legal Officer filed an initial ownership report on Form 3. The filing states no securities are beneficially owned and lists an amount of 0 shares. The date of the event requiring the statement is 10/06/2025. This is a routine disclosure establishing insider reporting status.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting ownership of 1,992,611 shares of Varex Imaging Corp common stock, representing 4.8% of the outstanding class. The filing states these shares are owned by investment funds advised or sub‑advised by Dimensional and that Dimensional disclaims beneficial ownership of the shares while acknowledging it may possess voting and/or investment power as adviser. Of the reported shares, 1,951,986 shares are listed as sole voting power and 1,992,611 as sole dispositive power. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Insider sale by Varex Imaging Corp officer under a pre-established plan. Karen L. Aranki, Chief Human Resources Officer and a company officer, reported the sale of 3,174 shares of Varex Imaging common stock on 09/19/2025 at an average price of $12.34 per share. After the transaction she beneficially owned 177 shares. The filing states the sales were effected pursuant to a 10b5-1 trading plan adopted June 17, 2025, indicating these trades followed an established written arrangement rather than ad hoc decisions. The Form 4 is signed and dated 09/22/2025.
Varex Imaging Corp (VREX) filed a Form 144 reporting a proposed sale of 3,174 common shares held by a person whose restricted stock vested on 05/15/2025. The shares are to be sold through Fidelity Brokerage Services LLC on or about 09/19/2025 on the NASDAQ, with an aggregate market value reported as $39,167.16. The filer indicates the shares were acquired as compensation upon vesting and reports no other sales in the past three months. The filing includes the standard Rule 144 representation that the seller is not aware of undisclosed material adverse information.
Varex Imaging Corporation reported that Kimberley Honeysett, its Senior Vice President, Chief Legal Officer, and Corporate Secretary, has agreed to transition out of the Chief Legal Officer role. She will remain CLO through October 3, 2025, then continue providing transition services as a non-executive employee or advisor through December 12, 2027, reporting to the Chief Executive Officer.
During the transition period, she will continue to receive her current salary, benefits, and, for fiscal year 2026, eligibility for a management incentive plan bonus. For the remainder of the continued service period, she will receive $100,000 in compensation, continued health insurance coverage, and other benefits described in her transition agreement, and will continue vesting in existing equity awards but will not receive new equity grants. The agreement also includes mutual releases, indemnification, and allows the company to terminate the arrangement for cause.
Jay K. Kunkel, a director of Varex Imaging Corp (VREX), sold 3,000 shares of the company's common stock on 08/14/2025 at $10.49 per share. After the sale, he beneficially owned 19,477 shares, reported as direct ownership. The Form 4 disclosure records the transaction and the sale price for each share.
The filing provides a straightforward record of insider liquidity: a director reduced his stake by 3,000 shares while maintaining a mid-sized direct holding in the company. No options, derivative transactions, or other compensatory arrangements are reported.
Varex Imaging Corporation (VREX) Form 144 filing: An insider proposes to sell 3,000 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $31,470. The shares represent restricted stock that vested and were acquired on 02/13/2023 as compensation. The sale is scheduled for approximately 08/14/2025 on NASDAQ. The filer reports 41,500,000 shares outstanding for this class. The filer also disclosed a prior sale of 2,575 shares on 06/18/2025 for gross proceeds of $20,007.75. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Pzena Investment Management LLC has filed Amendment No. 1 to Schedule 13G disclosing a passive ownership position in Varex Imaging Corporation (VREX).
- The value-oriented investment adviser now beneficially owns 4,244,977 common shares, representing 10.2 % of VREX’s outstanding stock.
- Sole voting power: 3,108,798 shares; sole dispositive power: the full 4,244,977 shares. No shares are held with shared voting or dispositive authority.
- The filing is made under Rule 13d-1(b) as an institutional investment adviser (IA), indicating the stake is held in the ordinary course of business and not for the purpose of influencing control.
- All shares are held on behalf of clients; no single client owns more than 5 % of the class.
- The filing date of the event is 30 June 2025; signature is dated 3 July 2025 by Chief Legal Risk & Compliance Officer Steven Coffey.
The >10 % threshold places Pzena among the largest institutional holders of VREX, potentially increasing trading liquidity and indicating external confidence in the company’s valuation, although the passive 13G designation suggests no activist intent.